Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 10/2021

01-10-2021 | Obesity | Review

Metabolomics in Bariatric Surgery: Towards Identification of Mechanisms and Biomarkers of Metabolic Outcomes

Authors: Jane Ha, Yeongkeun Kwon, Sungsoo Park

Published in: Obesity Surgery | Issue 10/2021

Login to get access

Abstract

Bariatric surgery has been widely performed for the treatment of obesity and type 2 diabetes. Efforts have been made to investigate the mechanisms underlying the metabolic effects achieved by bariatric surgery and to identify candidates who will benefit from this surgery. Metabolomics, which includes comprehensive profiling of metabolites in biological samples, has been utilized for various disease entities to discover pathophysiological metabolic pathways and biomarkers predicting disease progression or prognosis. Over the last decade, metabolomic studies on patients undergoing bariatric surgery have identified significant biomarkers related to metabolic effects. This review describes the significance, progress, and challenges for the future of metabolomics in the area of bariatric surgery.

Graphical abstract

Literature
1.
Panunzi S, Carlsson L, De Gaetano A, et al. Determinants of diabetes remission and glycemic control after bariatric surgery. Diabetes Care. 2016;39(1):166–74.PubMedCrossRef
2.
Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med. 2017;376(7):641–51.PubMedPubMedCentralCrossRef
3.
Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386(9997):964–73.PubMedCrossRef
4.
Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248–56. e5PubMedCrossRef
5.
Sjostrom L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56–65.PubMedCrossRef
6.
Heneghan HM, Meron-Eldar S, Brethauer SA, et al. Effect of bariatric surgery on cardiovascular risk profile. Am J Cardiol. 2011;108(10):1499–507.PubMedCrossRef
7.
Mummadi RR, Kasturi KS, Chennareddygari S, et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6(12):1396–402.PubMedCrossRef
8.
Skubleny D, Switzer NJ, Gill RS, et al. The impact of bariatric surgery on polycystic ovary syndrome: a systematic review and meta-analysis. Obes Surg. 2016;26(1):169–76.PubMedCrossRef
9.
Cohen RV, Pereira TV, Aboud CM, et al. Effect of gastric bypass vs best medical treatment on early-stage chronic kidney disease in patients with type 2 diabetes and obesity: a randomized clinical trial. JAMA Surg. 2020;155(8):e200420.PubMedPubMedCentralCrossRef
10.
11.
Attard JA, Dunn WB, Mergental H, et al. Systematic review: clinical metabolomics to forecast outcomes in liver transplantation surgery. OMICS. 2019;23(10):463–76.PubMedCrossRef
12.
Guasch-Ferre M, Hruby A, Toledo E, et al. Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis. Diabetes Care. 2016;39(5):833–46.PubMedPubMedCentralCrossRef
13.
Tulipani S, Griffin J, Palau-Rodriguez M, et al. Metabolomics-guided insights on bariatric surgery versus behavioral interventions for weight loss. Obesity (Silver Spring). 2016;24(12):2451–66.CrossRef
14.
15.
16.
17.
Pinu FR, Beale DJ, Paten AM, et al. Systems biology and multi-omics integration: viewpoints from the metabolomics research community. Metabolites. 2019;9(4):76.PubMedCentralCrossRef
18.
19.
Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov. 2016;15(7):473–84.PubMedCrossRef
20.
Laferrere B, Reilly D, Arias S, et al. Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. Sci Transl Med. 2011;3(80):80re2.PubMedPubMedCentralCrossRef
21.
Khoo CM, Muehlbauer MJ, Stevens RD, et al. Postprandial metabolite profiles reveal differential nutrient handling after bariatric surgery compared with matched caloric restriction. Ann Surg. 2014;259(4):687–93.PubMedCrossRef
22.
Liu R, Hong J, Xu X, et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med. 2017;23(7):859–68.PubMedCrossRef
23.
Palmisano S, Campisciano G, Silvestri M, et al. Changes in gut microbiota composition after bariatric surgery: a new balance to decode. J Gastrointest Surg. 2020;24(8):1736–46.PubMedCrossRef
24.
Guo Y, Huang ZP, Liu CQ, et al. Modulation of the gut microbiome: a systematic review of the effect of bariatric surgery. Eur J Endocrinol. 2018;178(1):43–56.PubMedCrossRef
25.
Wang M, Li L, Chen Y, et al. Role of gut microbiome and microbial metabolites in alleviating insulin resistance after bariatric surgery. Obes Surg. 2021;31(1):327–36.PubMedCrossRef
26.
Ha J, Kwon Y, Kim NH, et al. Discordance in prediction for prognosis of type 2 diabetes after metabolic surgery: comparison of the ABCD, DiaRem, and individualized metabolic surgery models. Ann Surg Treat Res. 2019;97(6):309–18.PubMedPubMedCentralCrossRef
27.
28.
Mihalik SJ, Michaliszyn SF. de las Heras J, et al. Metabolomic profiling of fatty acid and amino acid metabolism in youth with obesity and type 2 diabetes: evidence for enhanced mitochondrial oxidation. Diabetes Care. 2012;35(3):605–11.PubMedPubMedCentralCrossRef
29.
Newgard CB. Metabolomics and metabolic diseases: where do we stand? Cell Metab. 2017;25(1):43–56.PubMedCrossRef
30.
31.
Zheng Y, Li Y, Qi Q, et al. Cumulative consumption of branched-chain amino acids and incidence of type 2 diabetes. Int J Epidemiol. 2016;45(5):1482–92.PubMedPubMedCentralCrossRef
32.
33.
David J, Dardevet D, Mosoni L, et al. Impaired skeletal muscle branched-chain amino acids catabolism contributes to their increased circulating levels in a non-obese insulin-resistant fructose-fed rat model. Nutrients. 2019;11(2):355.PubMedCentralCrossRef
34.
Pedersen HK, Gudmundsdottir V, Nielsen HB, et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature. 2016;535(7612):376–81.PubMedCrossRef
35.
Arany Z, Neinast M. Branched chain amino acids in metabolic disease. Curr Diab Rep. 2018;18(10):76.PubMedCrossRef
36.
37.
Modesitt SC, Hallowell PT, Slack-Davis JK, et al. Women at extreme risk for obesity-related carcinogenesis: baseline endometrial pathology and impact of bariatric surgery on weight, metabolic profiles and quality of life. Gynecol Oncol. 2015;138(2):238–45.PubMedCrossRef
38.
Lopes TI, Geloneze B, Pareja JC, et al. Blood metabolome changes before and after bariatric surgery: a (1)H NMR-based clinical investigation. OMICS. 2015;19(5):318–27.PubMedCrossRef
39.
Tan HC, Hsu JW, Kovalik JP, et al. Branched-chain amino acid oxidation is elevated in adults with morbid obesity and decreases significantly after sleeve gastrectomy. J Nutr. 2020;150(12):3180–9.PubMedCrossRef
40.
Shah SH, Crosslin DR, Haynes CS, et al. Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss. Diabetologia. 2012;55(2):321–30.PubMedCrossRef
41.
Lips MA, Van Klinken JB, van Harmelen V, et al. Roux-en-Y gastric bypass surgery, but not calorie restriction, reduces plasma branched-chain amino acids in obese women independent of weight loss or the presence of type 2 diabetes. Diabetes Care. 2014;37(12):3150–6.PubMedCrossRef
42.
Kwon Y, Jang M, Lee Y, et al. Metabolomic analysis of the improvements in insulin secretion and resistance after sleeve gastrectomy: implications of the novel biomarkers. Obes Surg. 2021;31(1):43–52.PubMedCrossRef
43.
Wurtz P, Tiainen M, Makinen VP, et al. Circulating metabolite predictors of glycemia in middle-aged men and women. Diabetes Care. 2012;35(8):1749–56.PubMedPubMedCentralCrossRef
44.
45.
Tillin T, Hughes AD, Wang Q, et al. Diabetes risk and amino acid profiles: cross-sectional and prospective analyses of ethnicity, amino acids and diabetes in a South Asian and European cohort from the SABRE (Southall And Brent REvisited) Study. Diabetologia. 2015;58(5):968–79.PubMedPubMedCentralCrossRef
46.
Mutch DM, Fuhrmann JC, Rein D, et al. Metabolite profiling identifies candidate markers reflecting the clinical adaptations associated with Roux-en-Y gastric bypass surgery. PLoS One. 2009;4(11):e7905.PubMedPubMedCentralCrossRef
47.
Swierczynski J, Sledzinski T, Slominska E, et al. Serum phenylalanine concentration as a marker of liver function in obese patients before and after bariatric surgery. Obes Surg. 2009;19(7):883–9.PubMedCrossRef
48.
Eisenhofer G, Aneman A, Friberg P, et al. Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab. 1997;82(11):3864–71.PubMedCrossRef
49.
50.
Chaudhry S, Bernardes M, Harris PE, et al. Gastrointestinal dopamine as an anti-incretin and its possible role in bypass surgery as therapy for type 2 diabetes with associated obesity. Minerva Endocrinol. 2016;41(1):43–56.PubMed
51.
Ha J, Jang M, Kwon Y, et al. Metabolomic profiles predict diabetes remission after bariatric surgery. J Clin Med. 2020;9(12):3897.PubMedCentralCrossRef
52.
Oxenkrug G. Insulin resistance and dysregulation of tryptophan-kynurenine and kynurenine-nicotinamide adenine dinucleotide metabolic pathways. Mol Neurobiol. 2013;48(2):294–301.PubMedPubMedCentralCrossRef
53.
Moffett JR, Namboodiri MA. Tryptophan and the immune response. Immunol Cell Biol. 2003;81(4):247–65.PubMedCrossRef
54.
Favennec M, Hennart B, Caiazzo R, et al. The kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation. Obesity (Silver Spring). 2015;23(10):2066–74.CrossRef
55.
Favennec M, Hennart B, Verbanck M, et al. Post-bariatric surgery changes in quinolinic and xanthurenic acid concentrations are associated with glucose homeostasis. PLoS One. 2016;11(6):e0158051.PubMedPubMedCentralCrossRef
56.
Christensen MHE, Fadnes DJ, Rost TH, et al. Inflammatory markers, the tryptophan-kynurenine pathway, and vitamin B status after bariatric surgery. PLoS One. 2018;13(2):e0192169.PubMedPubMedCentralCrossRef
57.
Luo P, Yu H, Zhao X, et al. Metabolomics study of roux-en-Y gastric bypass surgery (RYGB) to treat type 2 diabetes patients based on ultraperformance liquid chromatography-mass spectrometry. J Proteome Res. 2016;15(4):1288–99.PubMedCrossRef
58.
Oh CM, Namkung J, Go Y, et al. Regulation of systemic energy homeostasis by serotonin in adipose tissues. Nat Commun. 2015;6:6794.PubMedCrossRef
59.
60.
Yabut JM, Crane JD, Green AE, et al. Emerging roles for serotonin in regulating metabolism: new implications for an ancient molecule. Endocr Rev. 2019;40(4):1092–107.PubMedPubMedCentralCrossRef
61.
Young RL, Lumsden AL, Martin AM, et al. Augmented capacity for peripheral serotonin release in human obesity. Int J Obes (Lond). 2018;42(11):1880–9.CrossRef
62.
Kwak SH, Park BL, Kim H, et al. Association of variations in TPH1 and HTR2B with gestational weight gain and measures of obesity. Obesity (Silver Spring). 2012;20(1):233–8.CrossRef
63.
Demerdash HM, Sabry AA, Arida EA. Role of serotonin hormone in weight regain after sleeve gastrectomy. Scand J Clin Lab Invest. 2018;78(1-2):68–73.PubMedCrossRef
64.
Fujitsuka N, Asakawa A, Hayashi M, et al. Selective serotonin reuptake inhibitors modify physiological gastrointestinal motor activities via 5-HT2c receptor and acyl ghrelin. Biol Psychiatry. 2009;65(9):748–59.PubMedCrossRef
65.
66.
Cussotto S, Delgado I, Anesi A, et al. Tryptophan metabolic pathways are altered in obesity and are associated with systemic inflammation. Front Immunol. 2020;11:557.PubMedPubMedCentralCrossRef
67.
Menni C, Hernandez MM, Vital M, et al. Circulating levels of the anti-oxidant indoleproprionic acid are associated with higher gut microbiome diversity. Gut Microbes. 2019;10(6):688–95.PubMedPubMedCentralCrossRef
68.
Floegel A, Stefan N, Yu Z, et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes. 2013;62(2):639–48.PubMedPubMedCentralCrossRef
69.
Gralka E, Luchinat C, Tenori L, et al. Metabolomic fingerprint of severe obesity is dynamically affected by bariatric surgery in a procedure-dependent manner. Am J Clin Nutr. 2015;102(6):1313–22.PubMedCrossRef
70.
Palau-Rodriguez M, Tulipani S, Marco-Ramell A, et al. Metabotypes of response to bariatric surgery independent of the magnitude of weight loss. PLoS One. 2018;13(6):e0198214.PubMedPubMedCentralCrossRef
71.
Igarashi K, Kashiwagi K. Modulation of cellular function by polyamines. Int J Biochem Cell Biol. 2010;42(1):39–51.PubMedCrossRef
72.
Ramos-Molina B, Queipo-Ortuno MI, Lambertos A, et al. Dietary and gut microbiota polyamines in obesity- and age-related diseases. Front Nutr. 2019;6:24.PubMedPubMedCentralCrossRef
73.
Fernandez-Garcia JC, Delpino-Rius A, Samarra I, et al. Type 2 diabetes is associated with a different pattern of serum polyamines: a case(-)control study from the PREDIMED-Plus Trial. J Clin Med. 2019;8(1):71.PubMedCentralCrossRef
74.
Ocana-Wilhelmi L, Cardona F, Garrido-Sanchez L, et al. Change in serum polyamine metabolome pattern after bariatric surgery in obese patients with metabolic syndrome. Surg Obes Relat Dis. 2020;16(2):306–11.PubMedCrossRef
75.
76.
Fahy E, Subramaniam S, Brown HA, et al. A comprehensive classification system for lipids. J Lipid Res. 2005;46(5):839–61.PubMedCrossRef
77.
Graessler J, Bornstein TD, Goel D, et al. Lipidomic profiling before and after roux-en-Y gastric bypass in obese patients with diabetes. Pharmacogenomics J. 2014;14(3):201–7.PubMedCrossRef
78.
Ramos-Molina B, Castellano-Castillo D, Alcaide-Torres J, et al. Differential effects of restrictive and malabsorptive bariatric surgery procedures on the serum lipidome in obese subjects. J Clin Lipidol. 2018;12(6):1502–12.PubMedCrossRef
79.
Lavie CJ, Milani RV, Mehra MR, et al. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol. 2009;54(7):585–94.PubMedCrossRef
80.
81.
Mihalik SJ, Goodpaster BH, Kelley DE, et al. Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring). 2010;18(9):1695–700.CrossRef
82.
Pournaras DJ, Glicksman C, Vincent RP, et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology. 2012;153(8):3613–9.PubMedPubMedCentralCrossRef
83.
Magkos F, Bradley D, Schweitzer GG, et al. Effect of Roux-en-Y gastric bypass and laparoscopic adjustable gastric banding on branched-chain amino acid metabolism. Diabetes. 2013;62(8):2757–61.PubMedPubMedCentralCrossRef
84.
Oberbach A, Bluher M, Wirth H, et al. Combined proteomic and metabolomic profiling of serum reveals association of the complement system with obesity and identifies novel markers of body fat mass changes. J Proteome Res. 2011;10(10):4769–88.PubMedCrossRef
85.
Fiamoncini J, Fernandes Barbosa C, Arnoni Junior JR, et al. Roux-en-Y gastric bypass surgery induces distinct but frequently transient effects on acylcarnitine, bile acid and phospholipid levels. Metabolites. 2018;8(4):83.
86.
Vice E, Privette JD, Hickner RC, et al. Ketone body metabolism in lean and obese women. Metabolism. 2005;54(11):1542–5.PubMedCrossRef
87.
Li X, Xu Z, Lu X, et al. Comprehensive two-dimensional gas chromatography/time-of-flight mass spectrometry for metabonomics: biomarker discovery for diabetes mellitus. Anal Chim Acta. 2009;633(2):257–62.PubMedCrossRef
88.
Gall WE, Beebe K, Lawton KA, et al. Alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One. 2010;5(5):e10883.PubMedPubMedCentralCrossRef
89.
Jullig M, Yip S, Xu A, et al. Lower fetuin-A, retinol binding protein 4 and several metabolites after gastric bypass compared to sleeve gastrectomy in patients with type 2 diabetes. PLoS One. 2014;9(5):e96489.PubMedPubMedCentralCrossRef
90.
Yoshida N, Kitahama S, Yamashita T, et al. Metabolic alterations in plasma after laparoscopic sleeve gastrectomy. J Diabetes Investig. 2021;12(1):123–9.PubMedCrossRef
91.
Wijayatunga NN, Sams VG, Dawson JA, et al. Roux-en-Y gastric bypass surgery alters serum metabolites and fatty acids in patients with morbid obesity. Diabetes Metab Res Rev. 2018;34(8):e3045.PubMedPubMedCentralCrossRef
92.
Shantavasinkul PC, Muehlbauer MJ, Bain JR, et al. Improvement in insulin resistance after gastric bypass surgery is correlated with a decline in plasma 2-hydroxybutyric acid. Surg Obes Relat Dis. 2018;14(8):1126–32.PubMedPubMedCentralCrossRef
93.
Kwon HN, Lee YJ, Kang JH, et al. Prediction of glycated hemoglobin levels at 3 months after metabolic surgery based on the 7-day plasma metabolic profile. PLoS One. 2014;9(11):e109609.PubMedPubMedCentralCrossRef
94.
Meikle PJ, Summers SA. Sphingolipids and phospholipids in insulin resistance and related metabolic disorders. Nat Rev Endocrinol. 2017;13(2):79–91.PubMedCrossRef
95.
Samczuk P, Luba M, Godzien J, et al. “Gear mechanism” of bariatric interventions revealed by untargeted metabolomics. J Pharm Biomed Anal. 2018;151:219–26.PubMedCrossRef
96.
Oberbach A, von Bergen M, Bluher S, et al. Combined serum proteomic and metabonomic profiling after laparoscopic sleeve gastrectomy in children and adolescents. J Laparoendosc Adv Surg Tech A. 2012;22(2):184–8.PubMedCrossRef
97.
98.
Haus JM, Kashyap SR, Kasumov T, et al. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes. 2009;58(2):337–43.PubMedPubMedCentralCrossRef
99.
Holland WL, Brozinick JT, Wang LP, et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 2007;5(3):167–79.PubMedCrossRef
100.
Huang H, Kasumov T, Gatmaitan P, et al. Gastric bypass surgery reduces plasma ceramide subspecies and improves insulin sensitivity in severely obese patients. Obesity (Silver Spring). 2011;19(11):2235–40.CrossRef
101.
Heneghan HM, Huang H, Kashyap SR, et al. Reduced cardiovascular risk after bariatric surgery is linked to plasma ceramides, apolipoprotein-B100, and ApoB100/A1 ratio. Surg Obes Relat Dis. 2013;9(1):100–7.PubMedCrossRef
102.
Wahlstrom A, Sayin SI, Marschall HU, et al. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24(1):41–50.PubMedCrossRef
103.
Thomas C, Pellicciari R, Pruzanski M, et al. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov. 2008;7(8):678–93.PubMedCrossRef
104.
105.
Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89(1):147–91.PubMedCrossRef
106.
Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A. 2006;103(4):1006–11.PubMedPubMedCentralCrossRef
107.
Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006;439(7075):484–9.PubMedCrossRef
108.
Patti ME, Houten SM, Bianco AC, et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring). 2009;17(9):1671–7.CrossRef
109.
Spinelli V, Lalloyer F, Baud G, et al. Influence of Roux-en-Y gastric bypass on plasma bile acid profiles: a comparative study between rats, pigs and humans. Int J Obes (Lond). 2016;40(8):1260–7.CrossRef
110.
Risstad H, Kristinsson JA, Fagerland MW, et al. Bile acid profiles over 5 years after gastric bypass and duodenal switch: results from a randomized clinical trial. Surg Obes Relat Dis. 2017;13(9):1544–53.PubMedCrossRef
111.
Bozadjieva N, Heppner KM, Seeley RJ. Targeting FXR and FGF19 to treat metabolic diseases-lessons learned from bariatric surgery. Diabetes. 2018;67(9):1720–8.PubMedPubMedCentralCrossRef
112.
Chaudhari SN, Harris DA, Aliakbarian H, et al. Bariatric surgery reveals a gut-restricted TGR5 agonist with anti-diabetic effects. Nat Chem Biol. 2021;17(1):20–9.PubMedCrossRef
113.
So SSY, Yeung CHC, Schooling CM, et al. Targeting bile acid metabolism in obesity reduction: a systematic review and meta-analysis. Obes Rev. 2020;21(7):e13017.PubMedCrossRef
114.
Schroeder BO, Backhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat Med. 2016;22(10):1079–89.PubMedCrossRef
115.
Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576–85.PubMedPubMedCentralCrossRef
116.
117.
Troseid M, Hov JR, Nestvold TK, et al. Major increase in microbiota-dependent proatherogenic metabolite TMAO one year after bariatric surgery. Metab Syndr Relat Disord. 2016;14(4):197–201.PubMedPubMedCentralCrossRef
118.
Aron-Wisnewsky J, Prifti E, Belda E, et al. Major microbiota dysbiosis in severe obesity: fate after bariatric surgery. Gut. 2019;68(1):70–82.PubMedCrossRef
119.
Shih DM, Wang Z, Lee R, et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J Lipid Res. 2015;56(1):22–37.PubMedPubMedCentralCrossRef
120.
Sowah SA, Riedl L, Damms-Machado A, et al. Effects of weight-loss interventions on short-chain fatty acid concentrations in blood and feces of adults: a systematic review. Adv Nutr. 2019;10(4):673–84.PubMedPubMedCentralCrossRef
121.
Silvestri C, Di Marzo V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab. 2013;17(4):475–90.PubMedCrossRef
122.
Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112(3):423–31.PubMedPubMedCentralCrossRef
123.
Bluher M, Engeli S, Kloting N, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006;55(11):3053–60.PubMedCrossRef
124.
125.
Horvath B, Mukhopadhyay P, Hasko G, et al. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Am J Pathol. 2012;180(2):432–42.PubMedPubMedCentralCrossRef
126.
Azar S, Sherf-Dagan S, Nemirovski A, et al. Circulating endocannabinoids are reduced following bariatric surgery and associated with improved metabolic homeostasis in humans. Obes Surg. 2019;29(1):268–76.PubMedCrossRef
127.
Quercioli A, Montecucco F, Pataky Z, et al. Improvement in coronary circulatory function in morbidly obese individuals after gastric bypass-induced weight loss: relation to alterations in endocannabinoids and adipocytokines. Eur Heart J. 2013;34(27):2063–73.PubMedCrossRef
128.
Zhao L, Ni Y, Yu H, et al. Serum stearic acid/palmitic acid ratio as a potential predictor of diabetes remission after Roux-en-Y gastric bypass in obesity. FASEB J. 2017;31(4):1449–60.PubMedCrossRef
129.
Ceperuelo-Mallafre V, Llaurado G, Keiran N, et al. Preoperative circulating succinate levels as a biomarker for diabetes remission after bariatric surgery. Diabetes Care. 2019;42(10):1956–65.PubMedCrossRef
130.
Lauti M, Kularatna M, Hill AG, et al. Weight regain following sleeve gastrectomy-a systematic review. Obes Surg. 2016;26(6):1326–34.PubMedCrossRef
131.
Karmali S, Brar B, Shi X, et al. Weight recidivism post-bariatric surgery: a systematic review. Obes Surg. 2013;23(11):1922–33.PubMedCrossRef
132.
Kwon Y, Jang M, Lee Y, et al. Amino acid metabolites and slow weight loss in the early postoperative period after sleeve gastrectomy. J Clin Med. 2020;9(8):2348.PubMedCentralCrossRef
133.
Abidi W, Nestoridi E, Feldman H, et al. Differential metabolomic signatures in patients with weight regain and sustained weight loss after gastric bypass surgery: a pilot study. Dig Dis Sci. 2020;65(4):1144–54.PubMedCrossRef
134.
Hanvold SE, Vinknes KJ, Bastani NE, et al. Plasma amino acids, adiposity, and weight change after gastric bypass surgery: are amino acids associated with weight regain? Eur J Nutr. 2018;57(7):2629–37.PubMedCrossRef
Metadata
Title
Metabolomics in Bariatric Surgery: Towards Identification of Mechanisms and Biomarkers of Metabolic Outcomes
Authors
Jane Ha
Yeongkeun Kwon
Sungsoo Park
Publication date
01-10-2021
Publisher
Springer US
Published in
Obesity Surgery / Issue 10/2021
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-021-05566-9

Other articles of this Issue 10/2021

Obesity Surgery 10/2021 Go to the issue

Original Contributions

Supervised Exercise Immediately After Bariatric Surgery: the Study Protocol of the EFIBAR Randomized Controlled Trial

Original Contributions

Evaluation of Resting Energy Expenditure in Subjects with Severe Obesity and Its Evolution After Bariatric Surgery

Review

A Scoping Review of Artificial Intelligence and Machine Learning in Bariatric and Metabolic Surgery: Current Status and Future Perspectives

Original Contributions

Confinement During the COVID-19 Pandemic After Metabolic and Bariatric Surgery—Associations Between Emotional Distress, Energy-Dense Foods, and Body Mass Index

Original Contributions

Hypoalbuminemia Predicts Serious Complications Following Elective Bariatric Surgery

Original Contributions

Prevalence of Peripheral Polyneuropathy Before and After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy